Drug Trial Radar · NCT07776743
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Jun 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.Industry
- Sponsor type
- Industry
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, controlled, multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of rocbrutinib (LP-168), an oral BTK inhibitor, in subjects with paramagnetic rim lesion (PRL)-positive relapsing-remitting multiple sclerosis (RRMS). Approximately 30 subjects with RRMS will be enrolled and randomized 2:1 to receive rocbrutinib 25 mg once daily (experimental arm) or dimethyl fumarate (DMF) delayed-release capsules 120 mg twice daily, escalated to 240 mg twice daily after 7 days (active control arm). The treatment period is 24 weeks; subjects in the experimental arm who remain relapse-free and are assessed by the investigator as having potential benefit may enter an open-label extension and continue rocbrutinib until Week 48 after randomization. The primary endpoint is the change from screening/baseline in the number, new number, and volume of PRL lesions detected by 7T MRI at Week 24.
Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
RocbrutinibDrug
Rocbrutinib (LP-168), a novel oral BTK inhibitor, film-coated tablet. Administered 25 mg orally once daily until completion of the treatment period (maximum 48 weeks including open-label extension).
Dimethyl FumarateDrug
DMF delayed-release capsules 120 mg/240 mg. Starting dose 120 mg twice daily; after 7 days, increase to maintenance dose 240 mg twice daily for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Screening/Baseline in the Number, New Number of Paramagnetic Rim Lesions (PRL) Detected by 7T MRITime frame: From screening/baseline to Week 24
- Change from Screening/Baseline in the Volume of Paramagnetic Rim Lesions (PRL) Detected by 7T MRITime frame: From screening/baseline to Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.